TOP2A gene copy number change in breast cancer. - Wikidata - awgldk - TriplyDB

TOP2A gene copy number change in breast cancer.

TOP2A gene copy number change in breast cancer.

http://www.wikidata.org/entity/Q37716023

about

Optimizing sparse sequencing of single cells for highly multiplex copy number profiling Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.

P2860

Q35561968-86360BAC-5641-4067-BDB2-E1B3498DB27C Q37606324-854C5DD0-34A9-4DB7-8D38-CE28B642D454 Q39305667-5F8EC2B5-6192-466D-B360-55D352ADC45B Q44217410-67F86506-ABD5-43D0-ADD4-8496FD79C3F4 Q49545664-74DEC313-7CC7-43E5-9BB4-C17CC882D924 Q52345488-41663D5A-9D52-4FAA-BEE7-A89C1E735352 Q55396428-BDA330D8-D96E-440E-B596-1252A6C5E7C3

P2860

TOP2A gene copy number change in breast cancer.

http://www.wikidata.org/entity/Q37716023

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TOP2A gene copy number change in breast cancer.

@en

TOP2A gene copy number change in breast cancer.

@nl

type

label

TOP2A gene copy number change in breast cancer.

@en

TOP2A gene copy number change in breast cancer.

@nl

prefLabel

TOP2A gene copy number change in breast cancer.

@en

TOP2A gene copy number change in breast cancer.

@nl

P1433

Q37716023-2663EEAD-8C8B-4A46-8F4C-F8D8425392B8

P1476

Q37716023-6F0B587B-ECA8-4236-872B-99DDA67936B7

P2093

Q37716023-25E3FD3E-CD80-4225-B611-74123537F441

Q37716023-5E54CE79-AB88-4BFF-8D56-458D74F51E3C

Q37716023-783865B5-5937-45DA-9543-39549DF10E28

Q37716023-9FE09573-5227-4FE3-98BF-0E00DFE11CFC

P2860

Q37716023-05742DB7-CEDA-417E-ADC7-3F9E7352D136

Q37716023-1DB3AAC1-DB66-4265-AD7C-CF60F92CC675

Q37716023-29A35F51-9625-4C93-9344-465E888EF80B

Q37716023-4A46C1EA-1501-4BBC-A25E-8DD2B0511AF9

Q37716023-65BDB261-0B8A-4EDA-8659-7532E6D93E6C

Q37716023-8063504B-0E1E-41D2-AFB5-BDC99F6D0389

Q37716023-8B15A8CB-D459-4146-B18C-F8B6B74D9479

Q37716023-A5D34839-1F76-40D6-B622-1A0AB964AF5C

Q37716023-A84400CD-DA29-4B8F-A2B7-0C6DE58A6D82

Q37716023-B1AFDFBB-00C1-4269-9B6F-75BFBE111166

P304

Q37716023-135D0049-A537-4E90-B86A-28287BC704D2

P31

Q37716023-AE09AF45-3942-418E-95DF-5296EBDFCF3C

P356

Q37716023-8A7712CE-F500-4C0A-A504-CE737265B1A6

P407

Q37716023-A26FAEC2-98B1-44E0-A9C3-7FEBC00DF09F

P433

Q37716023-C2654578-7159-4119-A16C-D502BFFAD24B

P478

Q37716023-B1BAB053-CC6C-4742-82A3-AACBC5705051

P50

Q37716023-5FD6C455-CD13-47B3-B44B-DC81BDA56E27

P577

Q37716023-31464A3C-C099-4A88-B630-2647FDC89BF6

P5875

Q37716023-48BE28E5-D7DE-4E7E-8C43-61A39C9E6CEB

P698

Q37716023-E898CD92-A9EE-4578-8BB3-6525936A7916

P932

Q37716023-D411E0B9-9376-4261-BAD1-E28D06DA340D

P356

JCLINPATH-2013-202052

P1433

Journal of Clinical Pathology

P1476

TOP2A gene copy number change in breast cancer.

@en

P2093

A M Bofin

http://www.w3.org/2001/XMLSchema#string

B Ytterhus

http://www.w3.org/2001/XMLSchema#string

M J Engstrøm

http://www.w3.org/2001/XMLSchema#string

S Opdahl

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Joint effects of nulliparity and other breast cancer risk factors.

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

P304

420-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCLINPATH-2013-202052

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259631125

http://www.w3.org/2001/XMLSchema#string

P698

24403186

http://www.w3.org/2001/XMLSchema#string

P932

3995265

http://www.w3.org/2001/XMLSchema#string